ArticleAdvances in therapy2025

Response to: Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.

Risa Kagan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.